Last reviewed · How we verify
Pabal (CARBETOCIN)
At a glance
| Generic name | CARBETOCIN |
|---|---|
| Sponsor | Ferring Pharmaceuticals Ltd |
| Drug class | carbetocin |
| Target | Oxytocin receptor |
| Modality | Recombinant protein |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Atony of uterus
- Prader-Willi syndrome
Common side effects
Key clinical trials
- Comparison of the Effect of Carbetocin Versus Oxytocin in the Prevention of Postpartum Hemorrhage After Emergency Caesarean Section in Antenatal Low-risk Patients (NA)
- Carbetocin Myocardium Trial 2014 Part 2 (PHASE4)
- Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage (PHASE4)
- Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy (NA)
- Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention (NA)
- Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone (NA)
- OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome (PHASE3)
- Effect of Extracellular Calcium on Carbetocin Mediated Contractility in Human Myometrium (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pabal CI brief — competitive landscape report
- Pabal updates RSS · CI watch RSS
- Ferring Pharmaceuticals Ltd portfolio CI